Drug Trial Radar · NCT07169279
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
77
Planned (sponsor's estimate)
Start
Nov 19, 2025
Primary completion
Mar 2030
Study completion Mar 2032
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 32 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.
Conditions
- Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administrationDrug
* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria. * The dose and number of minitablets will be calculated based on individual participant age and weight.
Infigratinib is provided as sprinkle capsules for daily oral administrationDrug
* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.
Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administrationDrug
* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.
Infigratinib is provided as sprinkle capsules for daily oral administrationDrug
* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single Ascending Dose Portion: Identify the dose of infigratinib to be used in each age cohort of the Phase 2 potion of the study (by assessing safety and PK of infigratinib and its active metabolites)Time frame: 2 weeks
- Phase 2 Portion: Confirm the doses to be used in each age cohort in the Phase 2b portion of the study (by assessing safety and PK of infigratinib and its active metabolites).Time frame: 52 weeks
- Phase 2b Portion: Evaluate the safety and efficacy of infigratinib in infants and children < 3 years old with ACH (by assessing AE's & SAE's)Time frame: 52 weeks
- Extension Portion: Evaluate the safety and efficacy of infigratinib in participants who completed the Phase 2 or Phase 2b portion of the study until they have reached 3 years old (+6 months) (by assessing AE's and SAE's)Time frame: 3 years and 6 months
Locations
12 sites in 7 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
Oakland, California · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
Madison, Wisconsin · Recruiting
Murdoch Children's Research Institute
Parkville, Victoria, Australia · Recruiting
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, Canada · Recruiting
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada · Recruiting
Paediatric Clinical Research Unit at Oslo University Hospital
Oslo, Norway · Recruiting
KK Women's and Children's Hospital
Singapore, Singapore · Recruiting
Unidad de Cirugía Artroscópica (UCA)
Vitoria-Gasteiz, Spain · Recruiting
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom · Recruiting
Manchester University NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Sheffield Children's NHS Foundation Trust
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.